IP Library Granted Patent US 10,183,999
Granted Patent B2
US 10,183,999 · App. 15/149,047 · Granted Jan 22, 2019

Optimized Fc variants and methods for their generation

Inventors: Gregory Alan Lazar (Pacifica, CA); Arthur J. Chirino (Camarillo, CA); Wei Dang (Pasadena, CA); John Desjarlais (Pasadena, CA); Stephen K. Doberstein (San Francisco, CA); Robert J. Hayes (Thousand Oaks, CA); Sher Bahadur Karki (Santa Monica, CA); Omid Vafa (Monrovia, CA)
Assignee: Xencor, Inc.
C07K16/283A61K39/395A61K39/3955A61K39/39566C07K16/00C07K16/22C07K16/2863C07K16/2875C07K16/2887C07K16/2893C07K16/2896C07K16/32C07K16/4291C12P21/005C40B30/02G06F19/12G06F19/16G06F19/22A61K2039/505C07K2317/14C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/41C07K2317/51C07K2317/52C07K2317/522C07K2317/524C07K2317/526C07K2317/56C07K2317/71C07K2317/72C07K2317/732C07K2317/734C07K2317/76C07K2317/77C07K2317/92C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,183,999
App. No.
15/149,047
Granted
Jan 22, 2019
Kind
B2
Abstract

The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.

Claims (19)

1. A nucleic acid encoding a polypeptide comprising an Fc variant of a human IgG Fc polypeptide, said Fc variant comprising an amino acid substitution at position 328 in the Fc region, wherein numbering is according to the EU index.

2. The nucleic acid according to claim 1 , wherein the substitution at position 328 is selected from the group consisting of M, E, and F.

3. The nucleic acid according to claim 1 , wherein the substitution at position 328 is 328F.

4. The nucleic acid according to claim 1 , wherein the human IgG Fc polypeptide is a human IgG1 Fc polypeptide.

5. An expression vector comprising the nucleic acid according to claim 1 .

6. A host cell comprising a nucleic acid according to claim 1 .

7. A host cell comprising an expression vector according to claim 5 .

8. A method of producing a polypeptide comprising: a) culturing a host cell according to claim 6 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide.

9. A method of producing a polypeptide comprising: a) culturing a host cell according to claim 7 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide.

10. A nucleic acid encoding a heavy chain of an antibody comprising an Fc variant of a human IgG Fc polypeptide, said Fc variant comprising an amino acid substitution at position 328 in the Fc region, wherein numbering is according to the EU index.

11. The nucleic acid according to claim 10 , wherein the substitution at position 328 is selected from the group consisting of M, E, and F.

12. The nucleic acid according to claim 10 , wherein the substitution is 328F.

13. The nucleic acid according to claim 10 , wherein the human IgG Fc polypeptide is a human IgG1 Fc polypeptide.

14. The nucleic acid according to claim 10 , wherein the antibody is a monoclonal antibody.

15. An expression vector comprising the nucleic acid according to claim 10 .

16. A host cell comprising a nucleic acid according to claim 10 .

17. A host cell comprising an expression vector according to claim 15 .

18. A method of producing a polypeptide comprising: a) culturing a host cell according to claim 16 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide.

19. A method of producing a polypeptide comprising: a) culturing a host cell according to claim 17 under conditions wherein said polypeptide is produced; and b) purifying said polypeptide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2016
From: LAZAR, GREGORY ALAN; CHIRINO, ARTHUR J.; DANG, WEI; DESJARLAIS, JOHN RUDOLPH; DOBERSTEIN, STEPHEN KOHL; HAYES, ROBERT J.; KARKI, SHER BAHADUR; VAFA, OMID
To: XENCOR, INC.
Reel/Frame 038750/0517 →
Continuity (9)
Division 13773485 · Feb 21, 2013
Division 13346604 · Jan 9, 2012
Division 11981822 · Oct 31, 2007
Division 10672280 · Sep 26, 2003
Provisional Application 60477839 · Jun 12, 2003
Provisional Application 60467606 · May 2, 2003
Provisional Application 60442301 · Jan 23, 2003
Provisional Application 60414433 · Sep 27, 2002
Related Publication 20160318993A1 · Nov 3, 2016
Cited By (6)
US 12,187,807 US 12,227,587 US 12,234,297 US 12,264,203 US 12,415,865 US 12,559,572